Minoryx

Bronze Sponsor

Minoryx is a clinical stage biotech company focusing on the development of novel therapies for orphan CNS diseases with high unmet medical needs. The company’s lead program, leriglitazone (MIN-102), a novel, selective PPARγ agonist, is currently being evaluated in X-linked Adrenoleukodystrophy (X-ALD) and Friedreich’s Ataxia. The company is backed by a syndicate of experienced investors, which includes Caixa Capital Risc, Roche Venture Fund, Ysios Capital, Kurma Partners, Fund+, Chiesi Ventures, S.R.I.W, Idinvest, SFPI-FPIM, HealthEquity and Sambrinvest, and has support from a network of other organizations. Minoryx was founded in 2011, is headquartered in Spain with Belgian facilities and has so far raised more than €85 million. www.minoryx.com


website

World Orphan Drug Congress

 

The World Orphan Drug Congress provides you with a one stop progressive scientific and strategic solution to the orphan drugs industry.

 

 

Events


World Orphan Drug Congress

Rare Disease Day

 

 

Contact us


To sponsor or exhibit:
Michael Hodge

Michael.hodge@terrapinn.com


To speak:
Wing-Yun Cheung

wing-yun.cheung@terrapinn.com


Nadia Konneh

nadia.konneh@terrapinn.com